Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P47989
UPID:
XDH_HUMAN
Alternative names:
-
Alternative UPACC:
P47989; Q16681; Q16712; Q4PJ16
Background:
Xanthine dehydrogenase/oxidase plays a pivotal role in purine degradation, catalyzing the transformation of hypoxanthine to xanthine and further to uric acid, while also contributing to reactive oxygen species generation. Its activity extends to the oxidation of aldehydes, albeit at a lower efficiency.
Therapeutic significance:
Xanthinuria 1, a disorder marked by excessive urinary excretion of xanthine and reduced serum uric acid levels, is directly linked to mutations affecting this enzyme. Understanding its mechanism could pave the way for innovative treatments for this and potentially other related metabolic disorders.